Carmine Valenza, MPH Student at Harvard T.H. Chan School of Public Health, shared a post on X:
“Happy to share our last contribution regarding ESR1m, endocrine-responsive mBC.
Patient selection according to clinical and molecular features is the key in the post-CDK4/6i setting.
Thanks to all the coauthors!”
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? published in ScienceDirect.
